Guardant Health (GH) saw its shares surge in the last session with trading volume being higher than average. The latest trend ...

Ahead of the 2025 J.P. Morgan Healthcare Conference scheduled to take place in a few days, Oppenheimer named five potential buyout candidates in biotech on Friday, naming obesity drug developer Viking ...

Regulators approved the first bespoke cell therapies for solid tumors this year, while drugmakers expanded and improved upon ...

Arcellx shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 82.

Arcellx shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 82.

Arcellx, Inc. (NASDAQ:ACLX), a U.S. biopharmaceutical company valued at $4.51 billion, has been making waves in the biotechnology sector with its innovative approach to cell therapy for multiple ...

Arcellx, Inc. (NASDAQ:ACLX), a U.S. biopharmaceutical company valued at $4.51 billion, has been making waves in the biotechnology sector with its innovative approach to cell therapy for multiple ...

Arcellx, Inc. (NASDAQ:ACLX – Get Free Report)’s share price rose 5.1% on Wednesday after UBS Group raised their price target on the stock from $106.00 to $114.00.UBS Group currently has a buy ...